NZ746608A - Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof - Google Patents
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereofInfo
- Publication number
- NZ746608A NZ746608A NZ746608A NZ74660811A NZ746608A NZ 746608 A NZ746608 A NZ 746608A NZ 746608 A NZ746608 A NZ 746608A NZ 74660811 A NZ74660811 A NZ 74660811A NZ 746608 A NZ746608 A NZ 746608A
- Authority
- NZ
- New Zealand
- Prior art keywords
- salt
- ylamino
- piperazin
- pyrrolo
- pyridin
- Prior art date
Links
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- NHANOMFABJQAAH-UHFFFAOYSA-N butanedioic acid;7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound OC(=O)CCC(O)=O.N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 NHANOMFABJQAAH-UHFFFAOYSA-N 0.000 abstract 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229950003687 ribociclib Drugs 0.000 abstract 1
- 229950010518 ribociclib succinate Drugs 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is crystalline ribociclib succinate (N,N-dimethyl-7-cyclopentyl-2-(5-(piperazin-1-yl)-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-carboxamide mono-succinic acid salt) and intermediates for the synthesis of ribociclib. Also disclosed is a pharmaceutical composition comprising: (a) a therapeutically effective amount of the salt and at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient for the treatment of diseases such as cancers which responds to inhibition of cyclin dependent kinase activity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41206410P | 2010-11-10 | 2010-11-10 | |
| NZ72954411 | 2011-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ746608A true NZ746608A (en) | 2020-05-29 |
Family
ID=71074418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ746608A NZ746608A (en) | 2010-11-10 | 2011-11-09 | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ746608A (en) |
-
2011
- 2011-11-09 NZ NZ746608A patent/NZ746608A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601754A (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| MX2021012478A (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor. | |
| MX2020011079A (en) | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolid in-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-c arboxamide hydrogen sulfate. | |
| MY186126A (en) | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | |
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| PH12014501504A1 (en) | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | |
| MX2011012337A (en) | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases. | |
| NZ609957A (en) | Heterocyclic compounds and uses thereof | |
| MY158193A (en) | Morpholino pyrimidines and their use in therapy | |
| WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
| MX2012013774A (en) | Soluble guanylate cyclase activators. | |
| MX2009008486A (en) | Imidazoquinolines as dual lipid kinase and mtor inhibitors. | |
| TW200635899A (en) | Chemical compounds | |
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| MY164274A (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| MX2012012952A (en) | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds. | |
| TN2013000324A1 (en) | 6 - cyclobutyl - 1, 5 - dihydro - pyrazolo [3, 4-d] pyrimidin- 4 - one derivatives their use as pde9a inhibitors | |
| MX2013014007A (en) | [1,3]oxazines. | |
| UA104489C2 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| MX2009004908A (en) | Chemical compounds. | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| MX2012002327A (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy. | |
| MX2014003194A (en) | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase. | |
| GB201302704D0 (en) | Therapeutic compounds | |
| AU2010275640A8 (en) | Benzoquinolizinium salt derivatives as anticancer agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 09 NOV 2021 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20200902 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2022 BY CPA GLOBAL Effective date: 20211022 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2023 BY CPA GLOBAL Effective date: 20221020 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2024 BY CPA GLOBAL Effective date: 20231019 |